Vikas Gupta
YOU?
Author Swipe
View article: Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1
Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1 Open
Introduction: The JAK inhibitor ruxolitinib is the first approved drug for the treatment of myelofibrosis (MF), with spleen volume and symptom reduction seen mostly within the first 6 months of treatment. Despite ruxolitinib's early effica…
View article: The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results
The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results Open
Background: Hepcidin dysregulation contributes to anemia of chronic inflammation observed in several malignancies, and hepcidin levels are elevated in myelofibrosis (MF). It has been proposed that activin receptor-like kinase-2 (ALK2 [ie, …
View article: Is There a Measurable Placebo Effect in Policy Announcements?
Is There a Measurable Placebo Effect in Policy Announcements? Open
This paper tests whether policy announcements generate a distinct "placebo" effect: an incremental same-day reaction beyond what is explained by the news sign (positive or negative) and the time remaining to implementation. We assemble a m…
View article: Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis
Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis Open
Patients with myelofibrosis (MF) who are resistant to or relapse after Janus kinase inhibitor (JAKi) therapy have limited treatment options and typically poor prognoses. CD123 is overexpressed in various myeloid malignancies, including MF.…
View article: ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis Open
Ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is the standard of care for symptomatic patients with myelofibrosis (MF). However, ∼70% of patients discontinue ruxolitinib after ∼5 years, a third of whom report suboptimal splenic respon…
View article: Spinal anaesthesia to caesarean section: Patient satisfaction
Spinal anaesthesia to caesarean section: Patient satisfaction Open
Patient satisfaction on spinal anaesthesia to caesarean section is of interest. Hence, data from 60 female doctors of various disciplines working in Bhopal city who underwent caesarean section under spinal anaesthesia during the last 5 yea…
View article: Limits on the Ejecta Mass During the Search for Kilonovae Associated with Neutron Star-Black Hole Mergers: A case study of S230518h, GW230529, S230627c and the Low-Significance Candidate S240422ed
Limits on the Ejecta Mass During the Search for Kilonovae Associated with Neutron Star-Black Hole Mergers: A case study of S230518h, GW230529, S230627c and the Low-Significance Candidate S240422ed Open
Neutron star-black hole (NSBH) mergers, detectable via their gravitational-wave (GW) emission, are expected to produce kilonovae (KNe). Four NSBH candidates have been identified and followed-up by more than fifty instruments since the star…
View article: Artificial Intelligence in Orthodontics: Evaluating Diagnostic Accuracy and Treatment Planning Efficiency
Artificial Intelligence in Orthodontics: Evaluating Diagnostic Accuracy and Treatment Planning Efficiency Open
Background: The integration of artificial intelligence (AI) in orthodontics promises to enhance diagnostic accuracy and optimize treatment planning. However, its clinical efficacy and reliability remain areas of active investigation. This …
View article: Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One – From timeliness of triage to cost-saving
Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One – From timeliness of triage to cost-saving Open
Myeloproliferative neoplasms (MPNs) are a group of rare clonal disorders of hematopoietic progenitor cells associated with disease-related symptoms, thrombotic events, and risk of transformation to acute myeloid leukemia (Tefferi, 2021). T…
View article: REMOVED: Genetic Landscape in Myelofibrosis Impacts Post-Hematopoietic Cell Transplantation Outcomes
REMOVED: Genetic Landscape in Myelofibrosis Impacts Post-Hematopoietic Cell Transplantation Outcomes Open
This abstract has been removed: please see Elsevier policy on article withdrawal (https://www.elsevier.com/about/policies-and-standards/article-withdrawal). This article has been removed at the request of the author. This abstract has been…
View article: Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study
Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study Open
Myelofibrosis (MF), a myeloproliferative neoplasm, was most commonly treated with hydroxyurea (HU) before approval of ruxolitinib (RUX), now the standard of care. Factors that influence real-world MF treatment patterns are not well underst…
View article: Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis
Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis Open
CPX-351 is approved for therapy-related acute myeloid leukemia (t-AML), and AML with myelodysplastic-related changes (AML-MRC). This approval was based on improved survival, remission rates, and similar safety compared to 7+3 regimen. In c…
View article: Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study Open
Introduction: Bromodomain and extra-terminal (BET) proteins are epigenetic readers that regulate expression of critical oncoproteins involved in the pathophysiology of hematologic malignancies, including myelofibrosis (MF). In a previous p…
View article: FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience
FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience Open
Introduction: Intensive induction chemotherapy (IC) is the main therapeutic modality for achieving complete remission (CR) with curative intent in patients (pts) with acute myeloid leukemia (AML). However, pts with newly diagnosed (ND) hig…
View article: Exhaled Breath Condensate Surveillance for <i>Aspergillus</i> in Acute Leukemia—a Pilot Trial
Exhaled Breath Condensate Surveillance for <i>Aspergillus</i> in Acute Leukemia—a Pilot Trial Open
Invasive fungal infections in patients with leukemia carry a high mortality rate, but early diagnosis has the potential to modify this natural history. A novel screening method using Aspergillus droplet-digital polymerase chain reaction in…
View article: Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis Open
With emerging new drugs in myelofibrosis (MF), a robust and harmonized framework for defining the severity of anemia and response to treatment will enhance clinical investigation and facilitate interstudy comparisons. Accordingly, the lead…
View article: Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1‐mutated AML
Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1‐mutated AML Open
Nucleophosmin‐1 (NPM1)‐mutated AML is a molecularly defined subtype typically associated with favorable treatment response and prognosis; however, its prognostic significance in AML evolving from an antecedent chronic myeloid malignancy is…
View article: Unmasking Job Satisfaction: Insights from Tribal India’s Nurses amongst the COVID-19 Pandemic
Unmasking Job Satisfaction: Insights from Tribal India’s Nurses amongst the COVID-19 Pandemic Open
Background: Even prior to the pandemic, India’s nursing workforce faced a severe shortage, exacerbating the challenges they now face during the global health crisis. When compared to the WHO norm of 1:300, the lack of trained nurses is muc…
View article: Stem Cell-Derived Gene Expression Scores Predict Survival and Blastic Transformation in Myelofibrosis
Stem Cell-Derived Gene Expression Scores Predict Survival and Blastic Transformation in Myelofibrosis Open
Purpose Myelofibrosis (MF) is the most severe myeloproliferative neoplasm (MPN) where there remains a need for improved risk stratification methods to better inform patient management. Since MF is a stem cell driven disease and stem cell i…
View article: HIF-1 activated by PIM1 assembles a pathological transcription complex and regulon that drives JAK2V617F MPN disease
HIF-1 activated by PIM1 assembles a pathological transcription complex and regulon that drives JAK2V617F MPN disease Open
Hypoxia-inducible factors (HIFs) are master transcriptional regulators, central to cellular survival under limited oxygen (hypoxia) and frequently activated within malignancy. Malignant context affects the role of HIFs within oncogenesis; …
View article: Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib
Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib Open
Pacritinib demonstrates consistent efficacy in patients with MF regardless of baseline platelet and hemoglobin counts.